All News
Filter News
Found 2,520 articles
-
To date, there are more than 72,000 confirmed and suspected cases of COVID-19 and 1,023 deaths from COVID-19, most in mainland China.
-
The U.S. Food and Drug Administration issued a statement on Friday outlining what the agency is doing at home and abroad in response to the outbreak, which has infected more than 73,000 people worldwide.
-
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
-
Coronavirus (COVID-19) Update: New Reporting Methods, Will Warm Weather Slow the Spread and U.S. ...
2/13/2020
The outbreak of the coronavirus, now called COVID-19, is taking some unexpected twists and turns. -
Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
2/13/2020
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the fourth quarter and full year 2019.
-
The World Health Organization (WHO) gave the coronavirus that began in Wuhan, China, an official name, COVID-19.
-
Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020
2/12/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2020 to report its fourth quarter and full year 2019 financial results,
-
Moderna Announces Pricing of Public Offering of Shares of Common Stock - Feb. 12, 2020
2/12/2020
Moderna, Inc. announced the pricing of an underwritten public offering of 26,315,790 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions.
-
Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates
2/10/2020
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020.
-
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
2/10/2020
Moderna, Inc. announced the first patient has been enrolled in the Phase 1/2 study evaluating the safety and tolerability of escalating doses of mRNA-3704 administered via intravenous infusion in patients with isolated methylmalonic acidemia due to MUT deficiency.
-
Moderna Announces Proposed Public Offering of Shares of Common Stock
2/10/2020
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has commenced an underwritten public offering of $500 million in shares of common stock.
-
GreenLight Taps Health Care Experts to Join Life Sciences Advisory Board
2/7/2020
As part of its expansion into human health, GreenLight Biosciences, Inc. is pleased to welcome the first members of its new Life Sciences Advisory Board.
-
Frequency Therapeutics Expands Leadership Team with Newly Appointed Chief People Officer and Head of Intellectual Property
2/7/2020
Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced new appointments to its leadership team. Wendy Arnold has joined the company as Chief People Officer, and Lisa Geller, Ph.D., J.D., is the company’s new Head of Intellectual Property.
-
Hot Topics Recap: Coronavirus
2/7/2020
Following are the latest Coronavirus news releases and story ideas for reporters, bloggers and media outlets.
-
China Coronavirus Update: Continued Spread, Run on Antivirals and Facemasks, Baby Diagnosed
2/6/2020
The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagn... -
The focus is on containment, although a number of organizations and companies are beginning work on vaccines.
-
Sandra Horning, M.D. To Join Moderna’s Board of Directors
2/3/2020
Former Genentech/Roche Chief Medical Officer and Head of Global Product Development will bring extensive global biopharma expertise to support Moderna’s late-stage development efforts
-
The spreading of the coronavirus that began in Wuhan, China has researchers and health officials worldwide studying the emerging virus and preparing to treat it and develop vaccines. With such an enormous global focus, it seems that new information about the virus and the infection is being publi...
-
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer
1/30/2020
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Melanie Ivarsson, Ph.D., M.B.A., will join the company as its Chief Development Officer
-
Alexion Reports Fourth Quarter and Full Year 2019 Results
1/30/2020
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019.